#United States #New York #Lead Plaintiff #Cytokinetics #CYTK

Levi & Korsinsky Alerts for Cytokinetics Investors

Levi & Korsinsky, LLP has recently issued a reminder for investors involved with Cytokinetics, Incorporated (NASDAQ: CYTK). A class action securities lawsuit has been initiated, and the deadline for notifying the Court to appoint a lead plaintiff is approaching on November 17, 2025. This legal action addresses various allegations of securities fraud that are believed to have impacted shareholders between December 27, 2023, and May 6, 2025.

Understanding the Lawsuit

The focal point of the complaint is rooted in claims that Cytokinetics made materially false and misleading statements concerning the timeline of its New Drug Application (NDA) for aficamten. Specifically, investors were led to believe that the U.S. Food and Drug Administration (FDA) would approve the NDA during the latter part of 2025, based on a PDUFA date set for September 26, 2025.

In reality, the situation was much more complex. The defendants allegedly failed to divulge critical risks associated with their choice to proceed without a Risk Evaluation and Mitigation Strategy (REMS), which could hinder the NDA's approval timeline. During an earnings call on May 6, 2025, it was disclosed that despite several pre-NDA meetings addressing safety monitoring and risk mitigation, the company opted not to include a REMS in its initial submission. This oversight contradicted prior assurances and misrepresented the company's regulatory timeline to investors.

Consequently, those who invested in Cytokinetics during this period might have acquired shares at inflated prices, leading to substantial financial losses once the truth about the regulatory hurdles and internal decision-making was exposed.

What Investors Should Do

If you suffered a loss as a result of your investment in Cytokinetics during the relevant timeframe, you need to take action before the deadline of November 17, 2025. You do not need to serve as a lead plaintiff to benefit from any potential recovery if the case is successful.

The firm ensures that participation in this class action lawsuit does not entail any out-of-pocket expenses for class members. This opens the pathway for investors to seek justice without financial burden, as there is no obligation to pay anything up front.

Why Choose Levi & Korsinsky

Levi & Korsinsky brings with it over two decades of experience in securing hundreds of millions of dollars for shareholders in similar situations. The firm has built a remarkable reputation for winning complex securities litigation cases, supported by a team of more than 70 professionals dedicated to representing the interests of investors. Remarkably, for seven consecutive years, it has been recognized as one of the top securities litigation firms in the United States according to the ISS Securities Class Action Services' Top 50 Report.

Contact Information

If you wish to learn more about the lawsuit or believe you may qualify as a class member, you can reach out to Joseph E. Levi, Esq. or Ed Korsinsky, Esq. at Levi & Korsinsky, LLP:

• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Email: [email protected]
• - Phone: (212) 363-7500

By staying informed and taking timely action, you maximize your chances of recovering your investment losses. Don’t miss out on this critical opportunity for recourse against alleged misconduct that adversely affected your financial well-being.

Ensure that you check the details of the lawsuit and participate before it's too late!